Deutsche Bank AG bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 46,884 shares of the biotechnology company’s stock, valued at approximately $3,165,000.
Several other large investors have also added to or reduced their stakes in ANAB. Persistent Asset Partners Ltd bought a new stake in AnaptysBio during the 2nd quarter worth approximately $39,000. Smartleaf Asset Management LLC boosted its position in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in AnaptysBio by 987.3% during the fourth quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock worth $83,000 after buying an additional 1,560 shares in the last quarter.
Wall Street Analysts Forecast Growth
ANAB has been the topic of several recent analyst reports. Barclays raised their price objective on AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Scotiabank downgraded shares of AnaptysBio to a “hold” rating and set a $70.00 target price for the company. in a report on Tuesday. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a research report on Monday. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Finally, Leerink Partners set a $90.00 price objective on shares of AnaptysBio in a research report on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $80.00.
AnaptysBio Trading Down 0.6%
AnaptysBio stock opened at $58.00 on Thursday. The business’s 50 day simple moving average is $58.58 and its 200 day simple moving average is $59.02. AnaptysBio, Inc. has a 12 month low of $11.40 and a 12 month high of $72.36. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -53.70 and a beta of 0.72.
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Featured Articles
- Five stocks we like better than AnaptysBio
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB – Free Report).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
